Myelofibrosis is a rare blood cancer that affects the bone marrow and can interfere with the normal production of blood cells. The condition belongs to a group of disorders called myeloproliferative neoplasms. As abnormal blood-forming cells accumulate, scar tissue can develop inside the bone marrow, reducing its ability to produce healthy blood cells. Treatment for myelofibrosis depends on several factors, including the type of disease, symptoms, blood counts, genetic findings, overall health, age, and estimated risk of disease progression.
Myelofibrosis is a disorder in which abnormal blood-forming cells and increased fibrous tissue develop within the bone marrow.
Healthy bone marrow produces red blood cells, white blood cells, and platelets. In myelofibrosis, abnormal signaling and inflammation can lead to progressive scarring. As the marrow becomes less effective, blood-cell production may shift to organs such as the spleen and liver.
This process can cause enlargement of the spleen, anemia, fatigue, abdominal discomfort, weight loss, night sweats, fever, itching, bone pain, and other symptoms.
Myelofibrosis can occur as primary myelofibrosis or develop after another myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia.
There is no single treatment plan that applies to every person with myelofibrosis.
Some people have minimal symptoms and relatively low-risk disease. In these circumstances, regular monitoring may be appropriate.
Others have significant symptoms, anemia, an enlarged spleen, low platelet counts, or biological features associated with a higher risk of progression.
Doctors commonly use risk-assessment systems to evaluate disease severity and estimate the likelihood of progression. Factors can include age, blood-cell counts, symptoms, blast-cell percentage, chromosome findings, and molecular abnormalities.
Risk assessment helps determine whether observation, symptom-directed treatment, drug therapy, clinical trials, or transplantation should be considered.
People with low-risk myelofibrosis who have few or no symptoms may not need immediate drug treatment.
Instead, the medical team may monitor:
Follow-up intervals depend on the individual situation.
Active monitoring does not mean that the disease is being ignored. It allows treatment to begin when symptoms, blood counts, spleen enlargement, or other findings indicate that intervention may provide meaningful benefit.
JAK inhibitors are among the most important medicines used to manage myelofibrosis.
The JAK-STAT signaling pathway is abnormally activated in myelofibrosis. Medicines that inhibit JAK signaling can reduce inflammatory signaling and may improve symptoms and spleen enlargement.
Four JAK inhibitors commonly used in myelofibrosis care include ruxolitinib, fedratinib, pacritinib, and momelotinib. The appropriate medicine depends on disease characteristics, platelet levels, anemia, previous treatment, symptoms, and other clinical factors.
Ruxolitinib is a JAK1 and JAK2 inhibitor that has an established role in myelofibrosis treatment.
It can reduce spleen enlargement and improve symptoms such as night sweats, fever, itching, and abdominal discomfort.
However, ruxolitinib can reduce blood-cell counts in some patients and may worsen anemia or thrombocytopenia. Blood counts therefore require regular monitoring during therapy.
Fedratinib is another JAK2-directed treatment used for certain adults with intermediate- or high-risk myelofibrosis.
It can be used in selected situations involving newly diagnosed disease or inadequate response to previous JAK inhibitor therapy.
Potential adverse effects include gastrointestinal symptoms and changes in blood counts. Thiamine status may also require attention because severe thiamine deficiency can cause serious complications.
Pacritinib is a JAK2 and IRAK1 inhibitor with a particular role in myelofibrosis associated with severe thrombocytopenia.
Low platelet counts can make treatment more complicated because some therapies may further suppress blood-cell production.
Pacritinib has been used for adults with intermediate- or high-risk primary or secondary myelofibrosis and very low platelet counts under its U.S. indication.
Treatment selection remains dependent on the complete clinical picture.
Momelotinib is another JAK inhibitor used in adults with intermediate- or high-risk myelofibrosis and anemia.
Anemia is a major problem in many people with myelofibrosis, and momelotinib has activity against JAK signaling while also affecting pathways involved in iron regulation.
Its role can be particularly relevant when anemia is a major component of the disease.
Anemia is one of the most common complications of myelofibrosis.
It can occur because scarred bone marrow cannot produce enough red blood cells. The spleen can also become enlarged and contribute to increased destruction or sequestration of blood cells.
Symptoms of anemia may include:
Treatment depends on the severity and underlying cause.
Red blood cell transfusions can provide rapid relief when anemia becomes severe or symptomatic.
Repeated transfusions may eventually contribute to iron accumulation, so people receiving frequent transfusions may require monitoring for iron overload.
Certain medicines can stimulate red blood cell production in selected patients.
Erythropoiesis-stimulating agents may be considered when laboratory findings suggest that they are likely to help.
Other approaches may be considered when anemia does not respond adequately.
Iron, vitamin B12, or folate deficiency can contribute to anemia.
Laboratory evaluation can help distinguish nutritional deficiencies from anemia caused primarily by myelofibrosis.
Replacing a documented deficiency may improve blood counts when deficiency is contributing to the problem.
An enlarged spleen, called splenomegaly, is a common feature of myelofibrosis.
The spleen may enlarge because it begins producing blood cells outside the bone marrow. This process is called extramedullary hematopoiesis.
A large spleen can cause:
JAK inhibitors are often used to reduce spleen size and improve related symptoms.
When drug treatment does not adequately control severe spleen-related problems, other approaches may occasionally be considered.
Surgical removal of the spleen, known as splenectomy, is not routinely used for every person with myelofibrosis.
It may be considered in selected circumstances when severe spleen enlargement causes significant complications and other approaches have not produced sufficient benefit.
Splenectomy carries risks, including bleeding, infection, blood clots, and other complications.
Because the spleen plays an important role in immune and blood functions, the decision requires careful specialist assessment.
Radiation therapy directed at the spleen can sometimes be considered when severe splenomegaly causes symptoms and other approaches are unsuitable.
The effect may be temporary, and radiation can also suppress blood-cell production.
For this reason, splenic radiation is generally reserved for particular clinical circumstances.
Myelofibrosis can cause bone and joint discomfort, itching, night sweats, fever, fatigue, and weight loss.
Treatment focuses on the underlying disease as well as individual symptoms.
Pain medicines may be used for bone or abdominal discomfort. Itching may respond to treatments aimed at the underlying inflammatory process or specific medicines selected by the medical team.
Severe fatigue may be related to anemia, inflammatory activity, poor sleep, nutritional problems, medication effects, or several factors occurring together.
Addressing the underlying cause is often more useful than treating fatigue alone.
Weight loss can occur because of inflammation, reduced appetite, early fullness from an enlarged spleen, or increased metabolic demands associated with the disease.
Nutritional assessment may be useful when weight loss is persistent.
Smaller meals spread throughout the day can sometimes help when spleen enlargement causes early fullness.
Adequate protein, calories, fluids, and essential nutrients are important for maintaining strength during chronic illness.
A dietitian experienced in cancer or hematology care may help develop an individualized nutrition plan.
Allogeneic hematopoietic stem cell transplantation is the only treatment with established potential to eradicate myelofibrosis in selected patients.
The procedure involves replacing abnormal blood-forming cells with healthy stem cells from a donor.
Before transplantation, conditioning treatment is generally used to suppress existing bone marrow and immune activity.
Donor stem cells are then infused and begin producing new blood cells.
Stem cell transplantation can offer the possibility of long-term remission, but it carries substantial risks.
Potential complications include severe infections, graft-versus-host disease, organ damage, graft failure, and treatment-related mortality.
Because of these risks, transplantation is generally considered for selected patients whose expected disease risk justifies the potential complications.
Transplantation is more commonly considered for people with higher-risk myelofibrosis who are medically fit enough to undergo the procedure.
Age is an important consideration, but it is not the only factor.
Doctors also evaluate:
A transplant center can perform a detailed evaluation to determine whether the potential benefits outweigh the risks.
Molecular testing is an important part of myelofibrosis evaluation.
Common driver mutations include JAK2, CALR, and MPL. Other genetic abnormalities can also provide information about disease biology and prognosis.
Genetic testing can help confirm the diagnosis, distinguish related disorders, assess risk, and sometimes influence treatment planning.
Not every person with myelofibrosis has one of the three major driver mutations, so a negative result for JAK2, CALR, or MPL does not automatically exclude the disease.
Myelofibrosis can develop as a secondary complication of other myeloproliferative neoplasms.
Polycythemia vera and essential thrombocythemia can sometimes progress to a fibrotic phase.
Treatment for secondary myelofibrosis is based on disease characteristics and follows many of the same principles used for primary myelofibrosis.
The previous blood disorder, duration of disease, mutation profile, blood counts, and symptoms can all influence treatment planning.
In a minority of cases, myelofibrosis can progress to acute myeloid leukemia.
This transformation is associated with a more aggressive disease course.
Warning signs can include rapidly worsening blood counts, increasing blast cells, worsening constitutional symptoms, or other evidence of disease progression.
Regular monitoring can help identify changes that require further evaluation.
Clinical trials are an important part of myelofibrosis research.
Researchers continue to investigate new JAK inhibitors, combinations of medicines, therapies aimed at anemia, agents targeting abnormal molecular pathways, and treatments designed to modify the underlying disease process.
Clinical trials may be considered when standard treatment does not provide adequate control or when a person meets the eligibility requirements for an investigational therapy.
Participation depends on disease characteristics, previous treatment, overall health, location, and study-specific criteria.